IDEAS home Printed from
MyIDEAS: Login to save this article or follow this journal

Systematic review of factors affecting pharmaceutical expenditures

  • Mousnad, Mohamed Awad
  • Shafie, Asrul Akmal
  • Ibrahim, Mohamed Izham
Registered author(s):

    To systematically identify the main factors contributing to the increase in pharmaceutical expenditures.

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

    File URL:
    Download Restriction: Full text for ScienceDirect subscribers only

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Article provided by Elsevier in its journal Health Policy.

    Volume (Year): 116 (2014)
    Issue (Month): 2 ()
    Pages: 137-146

    in new window

    Handle: RePEc:eee:hepoli:v:116:y:2014:i:2:p:137-146
    Contact details of provider: Web page:

    References listed on IDEAS
    Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

    as in new window
    1. Ulf-G Gerdtham & Magnus Johannesson & Bo Gunnarsson & Margareta Marcusson & Freddie Henriksson, 1998. "Price Indices of Drugs and the Switching to New Drugs: Two Empirical Examples," PharmacoEconomics, Springer Healthcare | Adis, vol. 13(1 Part 1), pages 71-80.
    2. Lisa L. Ioannides-Demos & Joseph E. Ibrahim & John J. McNeil, 2002. "Reference-Based Pricing Schemes: Effect on Pharmaceutical Expenditure, Resource Utilisation and Health Outcomes," PharmacoEconomics, Springer Healthcare | Adis, vol. 20(9), pages 577-591.
    3. Ulf-G. Gerdtham & Douglas Lundin, 2004. "Why Did Drug Spending Increase During the 1990s?: A Decomposition Based on Swedish Data," PharmacoEconomics, Springer Healthcare | Adis, vol. 22(1), pages 29-42.
    4. Bong-Min Yang, 2009. "The Future of Health Technology Assessment in Healthcare Decision Making in Asia," PharmacoEconomics, Springer Healthcare | Adis, vol. 27(11), pages 891-901.
    5. Ljungkvist, Mats-Olof & Andersson, David & Gunnarsson, Bo, 1997. "Cost and utilisation of pharmaceuticals in Sweden," Health Policy, Elsevier, vol. 41(Supplemen), pages S55-S69, September.
    6. Owen F. Humpage, 2008. "Rising relative prices or inflation: why knowing the difference matters," Economic Commentary, Federal Reserve Bank of Cleveland, issue Jun.
    7. Michael Dickson & Heinz Redwood, 1998. "Pharmaceutical Reference Prices: How do They Work in Practice?," PharmacoEconomics, Springer Healthcare | Adis, vol. 14(5), pages 471-479.
    8. Basu, Anirban & Jena, Anupam B. & Philipson, Tomas J., 2011. "The impact of comparative effectiveness research on health and health care spending," Journal of Health Economics, Elsevier, vol. 30(4), pages 695-706, July.
    9. Hanley, Gillian E. & Morgan, Steve, 2009. "Chronic catastrophes: Exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada," Social Science & Medicine, Elsevier, vol. 68(5), pages 919-924, March.
    10. Van Tielen, Rudy & Peys, Frank & Genaert, Jean, 1998. "The demographic impact on ambulatory pharmaceutical expenditure in Belgium," Health Policy, Elsevier, vol. 45(1), pages 1-14, July.
    11. Philippe Cavalié, 2003. "Is therapeutic innovation responsible for the increase in drug expenditure?," The European Journal of Health Economics, Springer, vol. 4(3), pages 184-194, September.
    12. Schneeweiss, Sebastian, 2007. "Reference drug programs: Effectiveness and policy implications," Health Policy, Elsevier, vol. 81(1), pages 17-28, April.
    13. Donald Vandegrift & Anusua Datta, 2006. "Prescription Drug Expenditures in the United States: The Effects of Obesity, Demographics, and New Pharmaceutical Products," Southern Economic Journal, Southern Economic Association, vol. 73(2), pages 515–529, October.
    14. Ulf-G. Gerdtham & Magnus Johannesson & Bo Gunnarsson & Margareta Marcusson & Freddie Henriksson, 1998. "The Effect of Changes in Treatment Patterns on Drug Expenditure," PharmacoEconomics, Springer Healthcare | Adis, vol. 13(1 Part 2), pages 127-134.
    15. Silvia M. Ess & Sebastian Schneeweiss & Thomas D. Szucs, 2003. "European Healthcare Policies for Controlling Drug Expenditure," PharmacoEconomics, Springer Healthcare | Adis, vol. 21(2), pages 89-103.
    16. Noyce, Peter R. & Huttin, Christine & Atella, Vicenzo & Brenner, Gerhard & Haaijer-Ruskamp, Flora M. & Hedvall, Maj-Britt & Mechtler, Reli, 2000. "The cost of prescription medicines to patients," Health Policy, Elsevier, vol. 52(2), pages 129-145, June.
    17. Daniella Perlroth & Dana Goldman & Alan Garber, 2010. "The potential impact of comparative effectiveness research on U.S. Health Care expenditures," Demography, Springer, vol. 47(1), pages S173-S190, March.
    18. Burstall, Michael L., 1997. "The management of the cost and utilisation of pharmaceuticals in the United Kingdom," Health Policy, Elsevier, vol. 41(Supplemen), pages S27-S43, September.
    19. Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
    20. Giuliani, Giovanni & Selke, Gisbert & Garattini, Livio, 1998. "The German experience in reference pricing," Health Policy, Elsevier, vol. 44(1), pages 73-85, April.
    21. Morgan, Steven G. & Agnew, Jonathan D. & Barer, Morris L., 2004. "Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia," Health Policy, Elsevier, vol. 68(3), pages 299-307, June.
    Full references (including those not matched with items on IDEAS)

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:116:y:2014:i:2:p:137-146. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Zhang, Lei)

    or ()

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.